ReviewResearch and practice in thrombosis and haemostasis2021
Menstruation, anticoagulation, and contraception: VTE and uterine bleeding.
Review in Research and practice in thrombosis and haemostasis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 19 citations in OpenAlex.
- Interdisciplinary management of gynecologic bleeding with anticoagulation: a recommended toolkit from the Foundation for Women and Girls with Blood Disorders+ Thrombosis Subcommittee.Journal of thrombosis and haemostasis : JTH · 2025Guideline
- Updated guidance for efficacy and safety outcomes for clinical trials in venous thromboembolism in children: communication from the ISTH SSC Subcommittee on Pediatric and Neonatal Thrombosis and Hemostasis.Journal of thrombosis and haemostasis : JTH · 2023Guideline
- Article
- Hormone-related thrombosis: duration of anticoagulation, risk of recurrence, and the role of hypercoagulability testing.Hematology. American Society of Hematology. Education Program · 2024Review
- Sex Matters: Policy on Reporting Sex as a Biological Variable at Research and Practice in Thrombosis and Hemostasis.Research and practice in thrombosis and haemostasis · 2023Article
- Apixaban for treatment of venous thromboembolism in an obese patient with Glanzmann thrombasthenia.Research and practice in thrombosis and haemostasis · 2023Article
- How do anticoagulants impact menstrual bleeding and quality of life? - The PERIOD study.Research and practice in thrombosis and haemostasis · 2023Article
- Challenging clinical scenarios for therapeutic anticoagulation: A practical approach.Thrombosis research · 2022Review
- Special Considerations for Women of Reproductive Age on Anticoagulation.Journal of general internal medicine · 2022Review
- The Journey to a Successful Illustrated Review.Research and practice in thrombosis and haemostasis · 2022Review
- Menstruation, anticoagulation, and contraception: VTE and uterine bleeding.Research and practice in thrombosis and haemostasis · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
Abstract
Abnormal or excessive menstrual bleeding affects one-third of reproductive-aged women. This number increases to 70% among women on direct oral anticoagulants (DOACs). While there is some variation in frequency of heavy menstrual bleeding (HMB) with different DOAC options, all menstruating individuals should receive counseling about the risk of HMB at the time of DOAC initiation. Management options include progestin-only therapies such as the levonorgestrel intrauterine system and etonogestrel subdermal implant or the progestin-only pill. Combined hormonal contraceptives and depot medroxyprogesterone acetate are associated with increased rates of thrombosis in nonanticoagulated women but may be continued, or even initiated, so long as therapeutic anticoagulation is ongoing. Procedural therapies, such as endometrial ablation, uterine artery embolization, or hysterectomy, are considerations for women who have completed childbearing and for whom more conservative measures are objectionable or ineffective. Given the high rates of HMB in women on DOACs, management strategies should be discussed even before heavy bleeding is diagnosed, particularly in women who experienced HMB prior to DOAC initiation. As iron deficiency with or without anemia is a common complication of HMB, complete blood count and ferritin levels should be monitored periodically, and iron deficiency should be treated with oral or intravenous iron supplementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.